(Q37791423)

23 August 2017

title

Insights into the stem cells of chronic myeloid leukemia (English)

1 reference

23 August 2017

main subject

chronic myeloid leukemia

0 references

1 reference

I Sloma

1

1 reference

23 August 2017

X Jiang

series ordinal

2

1 reference

23 August 2017

A C Eaves

series ordinal

3

1 reference

23 August 2017

C J Eaves

series ordinal

4

1 reference

23 August 2017

publication date

23 September 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

24

1 reference

23 August 2017

issue

11

1 reference

23 August 2017

page(s)

1823-1833

1 reference

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Clonal origin of chronic myelocytic leukemia in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Involvement of the B-lymphoid system in chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

BCR-ABL-transduced human cord blood cells produce abnormal populations in immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Leukemia stem cells in a genetically defined murine model of blast-crisis CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Cell culture studies in CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Modeling the initiation and progression of human acute leukemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Biological strategies for the selective manipulation of normal and leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-beta2 microglobulin-null mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Multilineage outgrowth of both malignant and normal hemopoietic progenitor cells from individual chronic myeloid leukemia patients in immunodeficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Humanized mice in translational biomedical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Stem cell biomarkers in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Changes in the proliferative activity of human hematopoietic stem cells in NOD/SCID mice and enhancement of their transplantability after in vivo treatment with cell cycle inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Transforming growth factor beta 1 selectively regulates early murine hematopoietic progenitors and inhibits the growth of IL-3-dependent myeloid leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

BCR – ABL accelerates C2-ceramide-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Intrinsic and extrinsic control of haematopoietic stem-cell self-renewal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Cytokine manipulation of primitive human hematopoietic cell self-renewal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Blast crisis in a murine model of chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

PML targeting eradicates quiescent leukaemia-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Chronic myelogenous leukemia stem cells: What's new?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Mutator phenotype of BCR--ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Occurrence of de novo ABL kinase domain mutations in primary bone marrow cells after BCR-ABL gene transfer and Imatinib mesylate selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

hOCT 1 and resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Identification of genes potentially involved in disease transformation of CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

BCR/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR/ABL-positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Chronic myelogenous leukemia molecular signature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Gene expression changes associated with progression and response in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Dietary glycine inhibits angiogenesis during wound healing and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

Cytogenetic studies on bone-marrow in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

7 January 2021

PERSISTENT MITOSIS OF TRANSFUSED HOMOLOGOUS LEUKOCYTES IN CHILDREN RECEIVING ANTILEUKEMIC THERAPY

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

7 January 2021

Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

7 January 2021

The challenges of targeting chronic myeloid leukemia stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

7 January 2021

BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

7 January 2021

Relationship of leukemia risk to radiation dose following cancer of the uterine corpus

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

7 January 2021

Leukemia mortality after X-ray treatment for ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

7 January 2021

bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

7 January 2021

Relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

7 January 2021

Lymphoid blast crises of chronic myelogenous leukemia represent stages in the development of B-cell precursors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

7 January 2021

Defective regulation of leukemic hematopoiesis in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

7 January 2021

Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

7 January 2021

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

7 January 2021

Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.159

7 January 2021

Identifiers

DOI

10.1038/LEU.2010.159

1 reference

Dimensions Publication ID

23 August 2017

1033073550

0 references

1 reference